These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 18445700)

  • 1. Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.
    Yu C; Friday BB; Yang L; Atadja P; Wigle D; Sarkaria J; Adjei AA
    Neuro Oncol; 2008 Jun; 10(3):309-19. PubMed ID: 18445700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
    Premkumar DR; Jane EP; Agostino NR; DiDomenico JD; Pollack IF
    Mol Carcinog; 2013 Feb; 52(2):118-33. PubMed ID: 22086447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
    Sutheesophon K; Kobayashi Y; Takatoku MA; Ozawa K; Kano Y; Ishii H; Furukawa Y
    Acta Haematol; 2006; 115(1-2):78-90. PubMed ID: 16424655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
    Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation.
    Yu C; Friday BB; Lai JP; McCollum A; Atadja P; Roberts LR; Adjei AA
    Clin Cancer Res; 2007 Feb; 13(4):1140-8. PubMed ID: 17317822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.
    Catley L; Weisberg E; Kiziltepe T; Tai YT; Hideshima T; Neri P; Tassone P; Atadja P; Chauhan D; Munshi NC; Anderson KC
    Blood; 2006 Nov; 108(10):3441-9. PubMed ID: 16728695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].
    Zhang L; Ma YP; Jia G
    Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):926-31. PubMed ID: 23363750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
    Maiso P; Carvajal-Vergara X; Ocio EM; López-Pérez R; Mateo G; Gutiérrez N; Atadja P; Pandiella A; San Miguel JF
    Cancer Res; 2006 Jun; 66(11):5781-9. PubMed ID: 16740717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
    Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
    J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.
    Ma Y; Liu W; Zhang L; Jia G
    Med Sci Monit; 2017 Oct; 23():5150-5157. PubMed ID: 29080899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Reversal effect of LBH589 alone or in combination with bortezomib on drug-resistance in myeloid leukemia and its mechanism].
    Jiang XJ; Meng FY; Zhou HS; Wang Q; Wu FQ; Huang KK; Huang M; Wang ZX; Chen WW
    Zhonghua Xue Ye Xue Za Zhi; 2011 Aug; 32(8):537-42. PubMed ID: 22338177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors.
    Asklund T; Kvarnbrink S; Holmlund C; Wibom C; Bergenheim T; Henriksson R; Hedman H
    Anticancer Res; 2012 Jul; 32(7):2407-13. PubMed ID: 22753697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.
    Feng R; Oton A; Mapara MY; Anderson G; Belani C; Lentzsch S
    Br J Haematol; 2007 Nov; 139(3):385-97. PubMed ID: 17910628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress.
    Dasmahapatra G; Lembersky D; Rahmani M; Kramer L; Friedberg J; Fisher RI; Dent P; Grant S
    Cancer Biol Ther; 2009 May; 8(9):808-19. PubMed ID: 19270531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
    Yu C; Rahmani M; Conrad D; Subler M; Dent P; Grant S
    Blood; 2003 Nov; 102(10):3765-74. PubMed ID: 12893773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells.
    Sato A; Asano T; Isono M; Ito K; Asano T
    BMC Urol; 2014 Aug; 14():71. PubMed ID: 25176354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
    Yu C; Friday BB; Lai JP; Yang L; Sarkaria J; Kay NE; Carter CA; Roberts LR; Kaufmann SH; Adjei AA
    Mol Cancer Ther; 2006 Sep; 5(9):2378-87. PubMed ID: 16985072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.
    Kim J; Guan J; Chang I; Chen X; Han D; Wang CY
    Mol Cancer Ther; 2010 Jul; 9(7):1977-84. PubMed ID: 20571067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.